Medicomp Systems, a provider of clinical data solutions, announced on Monday that its customer, Institut Jantung Negara (IJN), the National Heart Institute of Malaysia, has been granted Stage 7 validation by the Healthcare Information and Management Systems Society (HIMSS) Electronic Medical Record Adoption Model (EMRAM).
This is the highest level of digital health maturity recognised by HIMSS. IJN is the first hospital in Malaysia to achieve this milestone.
EMRAM Stage 7 requires hospitals to demonstrate fully paperless operations, robust data analytics capabilities, and the use of clinical data to measurably improve patient outcomes.
IJN, a 433-bed quaternary hospital and the largest integrated cardiovascular and thoracic care centre in Asia, partnered with Medicomp and its regional implementation partner APUK Co Ltd to deploy Quippe, Medicomp's evidence-based clinical documentation and decision support platform. Medicomp says that the implementation drove a rapid digital transformation, with IJN achieving 98% adoption of electronic clinical documentation. IJN had previously become the first hospital in Malaysia to achieve EMRAM Stage 6.
Dexcom highlights new diabetes outcomes and product roadmap at ATTD 2026
Curatis and Neupharma partner to develop corticorelin for peritumoral brain edema in Japan
Citius Oncology reports positive topline results from Phase 1 clinical trial of LYMPHIR combination
GenomOncology partners with WeTrials to support CNS cancer clinical trials
Immunic granted European patent for vidofludimus calcium dosing regimens
Agenus triggers USD20m milestone payment under Zydus manufacturing collaboration
HeartBeam and Mount Sinai partner to advance AI-enabled cardiac monitoring
Medicomp Systems client IJN in Malaysia granted Stage 7 validation from HIMSS EMRAM
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
Pfizer reports positive Phase 2 results for trispecific antibody in atopic dermatitis
Precision BioSciences receives FDA Fast Track designation for PBGENE-DMD
Zelluna partners with Etcembly to advance AI-driven TCR engineering for solid tumours
IDEAYA Biosciences enrols first patient in Phase 1 trial of PRMT5 inhibitor IDE892
Kelun-Biotech and Harbour BioMed receive China IND approval for atopic dermatitis therapy